Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus EZALLOR SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus EZALLOR SPRINKLE.
ASPIRIN; OMEPRAZOLE vs EZALLOR SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aspirin irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis and platelet aggregation. Omeprazole is a proton pump inhibitor that irreversibly binds to H+/K+-ATPase in gastric parietal cells, reducing gastric acid secretion.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
Aspirin 81 mg orally once daily plus omeprazole 20 mg orally once daily.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate half-life 2-3 hours at low doses, increasing to >20 hours at high doses due to saturable hepatic metabolism; clinically, dosing interval adjusted for antiplatelet effect (low dose) vs anti-inflammatory (high dose). Omeprazole: 0.5-1 hour; no accumulation on repeated dosing; metabolized via CYP2C19 and CYP3A4.
Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
Aspirin: renal elimination of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid); ~10% excreted unchanged in urine; dose-dependent due to saturable metabolism. Omeprazole: ~80% eliminated as metabolites in urine, ~20% in feces via biliary excretion.
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor